- Home
- TXMD vs AURE Comparison
TXMD vs AURE Comparison
Compare TXMD & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- AURE
- Stock Information
- Founded
- TXMD 2008
- AURE 2018
- Country
- TXMD United States
- AURE Hong Kong
- Employees
- TXMD N/A
- AURE N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- AURE Finance: Consumer Services
- Sector
- TXMD Health Care
- AURE Finance
- Exchange
- TXMD Nasdaq
- AURE Nasdaq
- Market Cap
- TXMD 17.6M
- AURE 19.4M
- IPO Year
- TXMD N/A
- AURE N/A
- Fundamental
- Price
- TXMD $1.63
- AURE $0.47
- Analyst Decision
- TXMD
- AURE
- Analyst Count
- TXMD 0
- AURE 0
- Target Price
- TXMD N/A
- AURE N/A
- AVG Volume (30 Days)
- TXMD 166.8K
- AURE 192.5K
- Earning Date
- TXMD 11-12-2025
- AURE 02-13-2026
- Dividend Yield
- TXMD N/A
- AURE N/A
- EPS Growth
- TXMD N/A
- AURE N/A
- EPS
- TXMD 0.03
- AURE N/A
- Revenue
- TXMD $2,796,000.00
- AURE $142,570.00
- Revenue This Year
- TXMD $427.09
- AURE N/A
- Revenue Next Year
- TXMD N/A
- AURE N/A
- P/E Ratio
- TXMD $259.70
- AURE N/A
- Revenue Growth
- TXMD 75.19
- AURE N/A
- 52 Week Low
- TXMD $0.70
- AURE $0.31
- 52 Week High
- TXMD $2.44
- AURE $2.70
- Technical
- Relative Strength Index (RSI)
- TXMD 55.64
- AURE N/A
- Support Level
- TXMD $1.55
- AURE N/A
- Resistance Level
- TXMD $2.08
- AURE N/A
- Average True Range (ATR)
- TXMD 0.28
- AURE 0.00
- MACD
- TXMD 0.01
- AURE 0.00
- Stochastic Oscillator
- TXMD 48.69
- AURE 0.00
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.